<p>WuXi Biologics (Cayman) Inc. announced that, based on a preliminary assessment of its unaudited consolidated management accounts for the year ended December 31, 2025, the company’s revenue is expected to increase by approximately 16.7% to RMB21,790 million. The gross profit margin rate is anticipated to expand by about 5 percentage points to 46.0%. Adjusted gross profit is projected to reach approximately RMB10,638 million, representing a year-on-year increase of around 25.5%. The company attributes these positive results to factors such as the ramp-up of its European manufacturing facility, cost savings and efficiency improvements from its business system and digitalization initiatives, as well as investment gains from its portfolio. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuxi Biologics (Cayman) Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260211-12021316), on February 10, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>

LABD

IBBQ

SBIO

Reuters

Direxion S&P Biotech Bear 3X

Invesco Nasdaq Biotechnology ETF

ALPS Medical Breakthrough

WuXi Biologics

Ark Genomic Revolution ETF

SPDR S&P Biotech

VG Health

iShares US Pharma

iShares Global Healthcare

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

Health Care Select Sector SPDR

Wuxi Biologics Expects 2025 Revenue to Rise 16.7% to RMB21.79 Billion